

## Clinical Policy: Belantamab Mafodotin-blmf (Blenrep)

Reference Number: LA.PHAR.469

Effective Date: 09.29.23

Last Review Date: 03.15.24

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### Description

Belantamab mafodotin-blmf (Blenrep<sup>®</sup>) is an anti-B-cell maturation antigen (BCMA) monoclonal antibody and microtubule inhibitor conjugate.

### FDA Approved Indication(s)\*

Blenrep is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent.

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

---

**\*GlaxoSmithKline (GSK), the manufacturer of Blenrep, voluntarily withdrew Blenrep after post-market data from the DREAMM-3 Phase 3 trial revealed Blenrep did not meet the requirements of the FDA Accelerated Approval regulation. The FDA withdrew its approval for the product (see Appendix D).**

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of Louisiana Healthcare Connections<sup>®</sup> that Blenrep is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Multiple Myeloma (must meet all):

1. Provider attestation of acknowledgement of FDA's request for withdrawal of product due to failure to demonstrate superior progression-free survival (PFS) compared to placebo;
2. Diagnosis of multiple myeloma;
3. Prescribed by or in consultation with an oncologist or hematologist;
4. Age  $\geq$  18 years;
5. Blenrep is prescribed as monotherapy;
6. Member has received  $\geq$  4 prior lines of therapy (see Appendix B for examples) that include all of the following (a, b, and c):
  - a. One proteasome inhibitor (e.g., bortezomib, Kyprolis<sup>®</sup>, Ninlaro<sup>®</sup>);

## CLINICAL POLICY

### Belantamab Mafodotin-blmf

- b. One immunomodulatory agent (e.g., Revlimid<sup>®</sup>, pomalidomide, Thalomid<sup>®</sup>);
  - c. One anti-CD38 antibody (e.g., Darzalex<sup>®</sup>/Darzalex Faspro<sup>™</sup>, Sarclisa<sup>®</sup>);
- \*Prior authorization may be required*
7. Request meets one of the following (a or b):\*
- a. Dose does not exceed 2.5 mg/kg every 3 weeks;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).
- \*Prescribed regimen must be FDA-approved or recommended by NCCN*

#### **Approval duration: 6 months**

#### **B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

## II. Continued Therapy

#### **A. Multiple Myeloma (must meet all):**

1. Provider attestation of acknowledgement of FDA's request for withdrawal of product due to failure to demonstrate superior PFS compared to placebo;
  2. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Blenrep for a covered indication and has received this medication for at least 30 days;
  3. Member is responding positively to therapy;
  4. Dose is  $\geq 1.9$  mg/kg every 3 weeks;
  5. If request is for a dose increase, request meets one of the following (a or b):\*
    - a. New dose does not exceed 2.5 mg/kg every 3 weeks;
    - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).
- \*Prescribed regimen must be FDA-approved or recommended by NCCN*

#### **Approval duration: 12 months**

#### **B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

## CLINICAL POLICY

### Belantamab Mafodotin-blmf

#### III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53 for Medicaid or evidence of coverage documents.

#### IV. Appendices/General Information

*Appendix A: Abbreviation/Acronym Key*

BCMA: B-cell maturation antigen

FDA: Food and Drug Administration

GSK: GlaxoSmithKline

PFS: progression free survival

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
bortezomib/Revlimid <sup>®</sup> (lenalidomide)/dexamethasone	Varies	Varies
bortezomib/cyclophosphamide/dexamethasone	Varies	Varies
bortezomib/doxorubicin (or liposomal doxorubicin)/dexamethasone	Varies	Varies
Kyprolis <sup>®</sup> (carfilzomib) Revlimid <sup>®</sup> (lenalidomide)/dexamethasone	Varies	Varies
Kyprolis <sup>®</sup> (carfilzomib)/cyclophosphamide/dexamethasone	Varies	Varies
Kyprolis <sup>®</sup> (carfilzomib – weekly or twice weekly)/dexamethasone	Varies	Varies
Ninlaro <sup>®</sup> (ixazomib)/Revlimid <sup>®</sup> (lenalidomide)/dexamethasone	Varies	Varies
Ninlaro <sup>®</sup> (ixazomib)/dexamethasone	Varies	Varies
Ninlaro <sup>®</sup> (ixazomib)/pomalidomide/dexamethasone	Varies	Varies
bortezomib/dexamethasone	Varies	Varies
bortezomib/Thalomid <sup>®</sup> (thalidomide)/dexamethasone	Varies	Varies
cyclophosphamide/Revlimid <sup>®</sup> (lenalidomide)/dexamethasone	Varies	Varies
Revlimid <sup>®</sup> (lenalidomide)/dexamethasone	Varies	Varies
VTD-PACE (dexamethasone/Thalomid <sup>®</sup> (thalidomide)/cisplatin/doxorubicin/cyclophosphamide/etoposide/bortezomib)	Varies	Varies
Revlimid <sup>®</sup> (lenalidomide)/low-dose dexamethasone	Varies	Varies
Darzalex <sup>®</sup> (daratumumab) or Darzalex Faspro <sup>™</sup> (daratumumab/hyaluronidase-fihj)/bortezomib/melphan/prednisone	Varies	Varies

## CLINICAL POLICY

### Belantamab Mafodotin-blmf

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Darzalex <sup>®</sup> (daratumumab) or Darzalex Faspro <sup>™</sup> (daratumumab/hyaluronidase-fihj)/bortezomib/dexamethasone	Varies	Varies
Darzalex <sup>®</sup> (daratumumab) or Darzalex Faspro <sup>™</sup> (daratumumab/hyaluronidase-fihj)/Revlimid <sup>®</sup> (lenalidomide)/dexamethasone	Varies	Varies
Darzalex <sup>®</sup> (daratumumab) or Darzalex Faspro <sup>™</sup> (daratumumab/hyaluronidase-fihj)	Varies	Varies
Darzalex <sup>®</sup> (daratumumab) or Darzalex Faspro <sup>™</sup> (daratumumab/hyaluronidase-fihj)/pomalidomide/dexamethasone	Varies	Varies
Empliciti <sup>®</sup> (elotuzumab)/Revlimid <sup>®</sup> (lenalidomide)/dexamethasone	Varies	Varies
Empliciti <sup>®</sup> (elotuzumab)/bortezomib/dexamethasone	Varies	Varies
Empliciti <sup>®</sup> (elotuzumab)/pomalidomide/dexamethasone	Varies	Varies
bendamustine/bortezomib/dexamethasone	Varies	Varies
bendamustine/Revlimid <sup>®</sup> (lenalidomide)/dexamethasone	Varies	Varies
panobinostat/bortezomib/dexamethasone	Varies	Varies
panobinostat/Kyprolis <sup>®</sup> (carfilzomib)	Varies	Varies
panobinostat/Revlimid <sup>®</sup> (lenalidomide)/dexamethasone	Varies	Varies
pomalidomide/cyclophosphamide/dexamethasone	Varies	Varies
pomalidomide/dexamethasone	Varies	Varies
pomalidomide/bortezomib/dexamethasone	Varies	Varies
pomalidomide/Kyprolis <sup>®</sup> (carfilzomib)/dexamethasone	Varies	Varies
Sarclisa <sup>®</sup> (isatuximab-irfc)/pomalidomide/dexamethasone	Varies	Varies

Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.

#### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): none reported
- Boxed warning(s): ocular toxicity
  - In clinical studies, Blenrep caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes. Because of these risks, Blenrep is only available through a restricted program, called the Blenrep REMS.

#### Appendix D: Withdrawal from Market

## CLINICAL POLICY

### Belantamab Mafodotin-blmf

- GSK, the manufacture of Blenrep, voluntarily withdrew Blenrep after post-market data from the DREAMM-3 Phase 3 trial revealed Blenrep did not meet the requirements of the FDA Accelerated Approval regulation.
  - Blenrep did not meet its primary endpoint of superior PFS compared to pomalidomide and dexamethasone (PomDex) for relapsed or refractory multiple myeloma.
  - The hazard ratio for PFS was 1.03 (95% CI: 0.72, 1.47). However, the observed median PFS was longer for Blenrep vs PomDex (11.2 vs 7 months).
- GSK has stopped new patient enrollment (as of November 22, 2022) into the Blenrep REMS.
- GSK recommends prescribers discuss the individual risk vs benefits to decide ongoing care.
- For enrolled patients deriving clinical benefits, Blenrep will continue to be available until GSK launches compassionate use program.
  - Details on compassionate use program will be provided directly to REMS enrolled prescriber.
- GSK recommends patients currently being treated with Blenrep should consult their healthcare providers.

#### V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Multiple myeloma	2.5 mg/kg* IV infusion every 3 weeks until disease progression or unacceptable toxicity	2.5 mg/kg/dose

*\*If dose reduction to < 1.9 mg/kg is required, discontinue therapy.*

#### VI. Product Availability

Lyophilized powder in a single-dose vial for reconstitution and further dilution for injection:  
100 mg

#### VII. References

1. Blenrep Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; February 2022. Available at: [www.blenrep.com](http://www.blenrep.com). Accessed January 13, 2023.
2. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncology*. 2020; 21(2): 207-221.
3. National Comprehensive Cancer Network. Multiple Myeloma Version 3.2023. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf). Accessed January 13, 2023.
4. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: [http://www.nccn.org/professionals/drug\\_compendium](http://www.nccn.org/professionals/drug_compendium). Accessed January 13, 2023.
5. GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation. November 22, 2022. Available at <https://www.gsk.com/en-gb/media/press->

## CLINICAL POLICY

### Belantamab Mafodotin-blmf

releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/. Accessed January 13, 2023.

#### Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9037	Injection, belantamab mafodontin-blmf, 0.5 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created	05.01.23	08.28.23
Annual review: no significant changes, removed inactive HCPCS code C9069; references reviewed and updated.	03.15.24	

#### Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or

## CLINICAL POLICY

### Belantamab Mafodotin-blmf

withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2024 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.